nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.0427	0.0427	CcSEcCtD
Gadoversetamide—Chest discomfort—Metformin—polycystic ovary syndrome	0.0391	0.0391	CcSEcCtD
Gadoversetamide—Accidental injury—Metformin—polycystic ovary syndrome	0.0391	0.0391	CcSEcCtD
Gadoversetamide—Ear pain—Metformin—polycystic ovary syndrome	0.0294	0.0294	CcSEcCtD
Gadoversetamide—Nasal congestion—Metformin—polycystic ovary syndrome	0.0276	0.0276	CcSEcCtD
Gadoversetamide—Injury—Metformin—polycystic ovary syndrome	0.0273	0.0273	CcSEcCtD
Gadoversetamide—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.0257	0.0257	CcSEcCtD
Gadoversetamide—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.0224	0.0224	CcSEcCtD
Gadoversetamide—Influenza—Metformin—polycystic ovary syndrome	0.0217	0.0217	CcSEcCtD
Gadoversetamide—Sweating increased—Metformin—polycystic ovary syndrome	0.0211	0.0211	CcSEcCtD
Gadoversetamide—Rhinitis—Metformin—polycystic ovary syndrome	0.0174	0.0174	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.0173	0.0173	CcSEcCtD
Gadoversetamide—Oedema peripheral—Metformin—polycystic ovary syndrome	0.0171	0.0171	CcSEcCtD
Gadoversetamide—Eye disorder—Metformin—polycystic ovary syndrome	0.0162	0.0162	CcSEcCtD
Gadoversetamide—Flushing—Metformin—polycystic ovary syndrome	0.0161	0.0161	CcSEcCtD
Gadoversetamide—Cardiac disorder—Metformin—polycystic ovary syndrome	0.0161	0.0161	CcSEcCtD
Gadoversetamide—Angiopathy—Metformin—polycystic ovary syndrome	0.0158	0.0158	CcSEcCtD
Gadoversetamide—Immune system disorder—Metformin—polycystic ovary syndrome	0.0157	0.0157	CcSEcCtD
Gadoversetamide—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.0156	0.0156	CcSEcCtD
Gadoversetamide—Chills—Metformin—polycystic ovary syndrome	0.0156	0.0156	CcSEcCtD
Gadoversetamide—Malnutrition—Metformin—polycystic ovary syndrome	0.0151	0.0151	CcSEcCtD
Gadoversetamide—Erythema—Metformin—polycystic ovary syndrome	0.0151	0.0151	CcSEcCtD
Gadoversetamide—Flatulence—Metformin—polycystic ovary syndrome	0.0149	0.0149	CcSEcCtD
Gadoversetamide—Dysgeusia—Metformin—polycystic ovary syndrome	0.0148	0.0148	CcSEcCtD
Gadoversetamide—Muscle spasms—Metformin—polycystic ovary syndrome	0.0145	0.0145	CcSEcCtD
Gadoversetamide—Vision blurred—Metformin—polycystic ovary syndrome	0.0142	0.0142	CcSEcCtD
Gadoversetamide—Tremor—Metformin—polycystic ovary syndrome	0.0142	0.0142	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.014	0.014	CcSEcCtD
Gadoversetamide—Malaise—Metformin—polycystic ovary syndrome	0.0136	0.0136	CcSEcCtD
Gadoversetamide—Syncope—Metformin—polycystic ovary syndrome	0.0136	0.0136	CcSEcCtD
Gadoversetamide—Palpitations—Metformin—polycystic ovary syndrome	0.0134	0.0134	CcSEcCtD
Gadoversetamide—Loss of consciousness—Metformin—polycystic ovary syndrome	0.0133	0.0133	CcSEcCtD
Gadoversetamide—Hypertension—Metformin—polycystic ovary syndrome	0.0131	0.0131	CcSEcCtD
Gadoversetamide—Chest pain—Metformin—polycystic ovary syndrome	0.0129	0.0129	CcSEcCtD
Gadoversetamide—Myalgia—Metformin—polycystic ovary syndrome	0.0129	0.0129	CcSEcCtD
Gadoversetamide—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.0128	0.0128	CcSEcCtD
Gadoversetamide—Discomfort—Metformin—polycystic ovary syndrome	0.0127	0.0127	CcSEcCtD
Gadoversetamide—Oedema—Metformin—polycystic ovary syndrome	0.0123	0.0123	CcSEcCtD
Gadoversetamide—Shock—Metformin—polycystic ovary syndrome	0.0121	0.0121	CcSEcCtD
Gadoversetamide—Nervous system disorder—Metformin—polycystic ovary syndrome	0.0121	0.0121	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.0121	0.0121	CcSEcCtD
Gadoversetamide—Skin disorder—Metformin—polycystic ovary syndrome	0.012	0.012	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.0119	0.0119	CcSEcCtD
Gadoversetamide—Anorexia—Metformin—polycystic ovary syndrome	0.0118	0.0118	CcSEcCtD
Gadoversetamide—Hypotension—Metformin—polycystic ovary syndrome	0.0115	0.0115	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.0112	0.0112	CcSEcCtD
Gadoversetamide—Paraesthesia—Metformin—polycystic ovary syndrome	0.0111	0.0111	CcSEcCtD
Gadoversetamide—Dyspnoea—Metformin—polycystic ovary syndrome	0.011	0.011	CcSEcCtD
Gadoversetamide—Somnolence—Metformin—polycystic ovary syndrome	0.011	0.011	CcSEcCtD
Gadoversetamide—Dyspepsia—Metformin—polycystic ovary syndrome	0.0109	0.0109	CcSEcCtD
Gadoversetamide—Decreased appetite—Metformin—polycystic ovary syndrome	0.0107	0.0107	CcSEcCtD
Gadoversetamide—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.0107	0.0107	CcSEcCtD
Gadoversetamide—Fatigue—Metformin—polycystic ovary syndrome	0.0106	0.0106	CcSEcCtD
Gadoversetamide—Constipation—Metformin—polycystic ovary syndrome	0.0105	0.0105	CcSEcCtD
Gadoversetamide—Feeling abnormal—Metformin—polycystic ovary syndrome	0.0102	0.0102	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.0101	0.0101	CcSEcCtD
Gadoversetamide—Urticaria—Metformin—polycystic ovary syndrome	0.0098	0.0098	CcSEcCtD
Gadoversetamide—Abdominal pain—Metformin—polycystic ovary syndrome	0.00975	0.00975	CcSEcCtD
Gadoversetamide—Asthenia—Metformin—polycystic ovary syndrome	0.00885	0.00885	CcSEcCtD
Gadoversetamide—Pruritus—Metformin—polycystic ovary syndrome	0.00873	0.00873	CcSEcCtD
Gadoversetamide—Diarrhoea—Metformin—polycystic ovary syndrome	0.00844	0.00844	CcSEcCtD
Gadoversetamide—Dizziness—Metformin—polycystic ovary syndrome	0.00816	0.00816	CcSEcCtD
Gadoversetamide—Vomiting—Metformin—polycystic ovary syndrome	0.00784	0.00784	CcSEcCtD
Gadoversetamide—Rash—Metformin—polycystic ovary syndrome	0.00778	0.00778	CcSEcCtD
Gadoversetamide—Dermatitis—Metformin—polycystic ovary syndrome	0.00777	0.00777	CcSEcCtD
Gadoversetamide—Headache—Metformin—polycystic ovary syndrome	0.00773	0.00773	CcSEcCtD
Gadoversetamide—Nausea—Metformin—polycystic ovary syndrome	0.00733	0.00733	CcSEcCtD
